Research Summaries

Retatrutide outcomesand observed effects.

A plain-English summary of published clinical trial data on Retatrutide (LY3437943) — its receptor mechanism, weight-loss and glycaemic findings, and the adverse events recorded in research settings. Written for researchers who need context, not clinical advice.

Research-use only

Retatrutide is not a licensed medicine in the UK and is not approved by the MHRA. The material supplied by RETA MED UK is intended for laboratory, in-vitro and scientific research use only. The trial summaries below describe findings from controlled studies; they do not predict outcomes in any other setting and must not be interpreted as medical guidance.

Mechanism

Three metabolic targets,one investigational molecule.

GLP-1

Slows gastric emptying and enhances satiety signalling. GLP-1 agonism is associated with reduced food intake and improved post-prandial glucose handling.

GIP

Potentiates glucose-dependent insulin release and may influence lipid storage and energy partitioning in adipose tissue.

Glucagon

Increases energy expenditure and promotes hepatic fat metabolism. Its inclusion distinguishes retatrutide from single- and dual-agonist compounds.

By engaging all three receptors simultaneously, retatrutide allows researchers to study how overlapping incretin and energy-expenditure pathways interact. This triple-agonist design is the basis of the compound's scientific interest.

Clinical trials

Published research,summarised clearly.

Phase 2New England Journal of Medicine

Triple–Hormone-Receptor Agonist Retatrutide for Obesity

A randomised, double-blind, placebo-controlled dose-ranging study. At 48 weeks, mean weight reductions reached 22.8% at 8 mg and 24.2% at 12 mg among participants without diabetes. The most commonly reported adverse events were gastrointestinal.

Up to 24.2% mean body-weight reduction at 12 mg by week 48
Up to 17.5% mean weight reduction at 24 weeks in higher-dose groups
Nausea, diarrhoea, vomiting and constipation were the most frequent events
Most events were dose-dependent and diminished over time or with dose adjustment

Read the original study

Phase 2The Lancet

Retatrutide for people with type 2 diabetes

A randomised, double-blind, placebo- and active-controlled trial in adults with type 2 diabetes. Retatrutide showed dose-dependent reductions in HbA1c and body weight compared with placebo and active comparators.

Significant HbA1c reduction versus placebo at 12 weeks
Clinically meaningful weight loss in the diabetes population
Gastrointestinal symptoms were the leading adverse events
No new safety signals were identified relative to the class profile

Read the original study

Phase 2aNature Medicine

Retatrutide in metabolic dysfunction-associated steatotic liver disease (MASLD)

A substudy of the Phase 2 obesity programme examining retatrutide in adults with MASLD. The compound was associated with reductions in liver fat fraction and improvements in related metabolic markers.

Substantial relative reduction in liver fat fraction at 48 weeks
Benefits aligned with the degree of weight reduction observed
Safety profile consistent with the broader Phase 2 programme
Further research is needed to confirm long-term histological outcomes

Read the original study

Phase 3The Lancet

TRANSCEND-T2D-1: efficacy and safety in type 2 diabetes

A double-blind, randomised Phase 3 trial evaluating retatrutide in people with type 2 diabetes and inadequate glycaemic control. The study assessed glycaemic endpoints, body weight and safety over a longer treatment period.

Robust HbA1c and fasting glucose improvements versus placebo
Sustained, dose-dependent weight reduction
Gastrointestinal events remained the most common adverse events
Long-term follow-up continues to refine the benefit-risk profile

Read the original study

Retatrutide 40mg pen with sterile needle tips and alcohol wipes

Adverse events

What the trialsrecorded.

The following adverse events were reported during clinical trials of retatrutide. They are presented here as research observations, not as a guide to personal risk or a substitute for medical advice.

Nausea

Reported in a substantial minority of participants, most often during dose escalation. Typically mild-to-moderate and transient.

Diarrhoea

Dose-dependent and commonly reported alongside other GI symptoms. Usually self-limiting after the body adapts.

Vomiting

Less frequent than nausea but still among the leading adverse events. Dose-escalation strategies appear to reduce incidence.

Constipation

Observed alongside the GI spectrum. Severity was generally mild and manageable in the trial setting.

Decreased appetite

A pharmacologically expected effect linked to GLP-1 and glucagon receptor signalling. Recorded as an adverse event in some participants.

Injection-site reactions

Localised redness, itching or swelling reported at a low frequency. Similar to other injectable peptide research programmes.

Gallbladder-related events

Cholelithiasis and biliary events were monitored. Rates were consistent with the class and the degree of weight loss observed.

Heart rate increase

Small mean increases in heart rate were observed, consistent with glucagon-receptor engagement. Clinically monitored in trials.

How to read this data

Clinical trial outcomes describe what happened under controlled conditions in a specific population. They do not predict what will happen in every laboratory model, and they are not evidence that the same effects would occur outside the study.

Adverse event reporting also depends on how a study is designed: what questions are asked, how doses are escalated, and how long participants are followed. Always consult the original publication before drawing conclusions for your own research.

Research-grade Retatrutide, UK supplied.

Our 40mg pre-filled pen is supplied for laboratory and in-vitro research only. Every batch is purity-tested by HPLC and mass spectrometry, with certificates available on request.

Purchase the 40mg pen Read the full explainer